J&J pauses Alzheimer’s study enrolment Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 19 February, 2026

AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.

presented by Lessons in Cat­e­go­ry Cre­ation: In Con­ver­sa­tion with Bob­by Aza­mi­an, CEO Tar­sus Phar­ma­ceu­ti­cals

news J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug Led by former Trump official, Altesa raises $75M to advance respiratory med Pharma signals it’s done negotiating as Trump’s drug pricing effort marches on

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group United States Vice President, Drug Metabolism & Pharmacokinetics (DMPK) C4 Therapeutics Watertown, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Innovation in biopharmaceuticals: A conversation with Fujifilm leaders sponsored by Fujifilm

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

ENDPOINTS PHARMA Exclusive: Reversal on Moderna's flu application follows atypical path through FDA •  FDA reverses course, will review Moderna’s flu vaccine Senate health committee chair plots future FDA changes Charles River sees demand increase, says clients are 'back to work' as tariff uncertainties fade J&J pours $1B into new cell therapy site in Pennsylvania

in case you missed it 1. Updated: Novartis signs macrocyclic deal with Unnatural Products 2. Chinese biotech claims promising brain cancer results using debated approach 3. Faeth goes public in merger with Sensei, nets $200M in stock sale 4. News Briefing Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results 5. Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront 6. Paragon's latest biotech will try to slow Alzheimer's like Roche 7.